BI-FUNCTIONAL COMPOUNDS AND METHODS FOR TARGETED UBIQUITINATION OF ANDROGEN RECEPTOR
The present invention relates to bi-functional compounds which function to recruit endogenous proteins to an E3 ubiquitin ligase for degradation, and methods for using same. More specifically, the present disclosure provides specific proteolysis targeting chimera (PROTAC) molecules which find utility as modulators of targeted ubiquitination of a variety of polypeptides and other proteins, in particular the androgen receptor of a slice variant of AR which lacks the LBD, labelled as AR-V7, which are then degraded and/or otherwise inhibited by the compounds as described herein.
1 . A compound having a chemical structure ARB-E3LB or ARB-L-E3LB, wherein ARB is an AR binding moiety that does not bind to a ligand binding domain, E3LB is an E3 ligase binding moiety, and L is a linker coupling the AR binding moiety to the E3 ligase binding moiety, wherein the ARB is a moiety comprising a bridged bicyclic 7-12 membered heterocycloalkyl ring (e.g., a bridged morpholine).
2 . The compound according to claim 1 , wherein the AR binding moiety binds to one more of AR splice variants V1 to V15, for example, to AR splice variant V7 (AR-V7).
3 . The compound according to claim 1 , wherein the AR binding moiety is selected from:
wherein:
A is a bridged bicyclic 7-12 membered heterocycloalkyl ring (e.g., with 1-4 heteroatoms, such as a bridged morpholine), which is optionally substituted by one or more groups selected from halo (e.g., fluoro), hydroxy, nitro, cyano, C 1-6 alkyl (e.g., methyl), C 2-6 alkenyl (e.g., vinyl), or C 2-6 alkynyl (e.g., ethynyl), NR 2 R 3 , haloC 1-6 alkyl (e.g., CH 2 F, CHF 2 , CF 3 ), C 1-6 alkoxy (e.g., methoxy), C 3-6 cycloalkyl (e.g., cyclopropyl), aryl, heteroaryl, and 3-6 membered heterocycloalkyl (e.g., with 1-4 heteroatoms), wherein each of said alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, aryl, heteroaryl and heterocycloalkyl are independently optionally substituted by one or more halo, hydroxy, nitro, cyano, C 1-6 alkyl (e.g., methyl), haloC 1-6 alkyl (e.g., CH 2 F, CHF 2 , CF 3 ), C 1-6 alkoxy (e.g., methoxy), or C 3-6 cycloalkyl (e.g., cyclopropyl);
B is an aryl (e.g., phenyl) or heteroaryl (e.g., pyridyl or imidazolyl) ring, optionally substituted by one or more groups selected from halo (e.g., fluoro), hydroxy, nitro, cyano, C 1-6 alkyl (e.g., methyl), C 2-6 alkenyl (e.g., vinyl), or C 2-6 alkynyl (e.g., ethynyl), NR 2 R 3 , haloC 1-6 alkyl (e.g., CH 2 F, CHF 2 , CF 3 ), C 1-6 alkoxy (e.g., methoxy), C 3-6 cycloalkyl (e.g., cyclopropyl), aryl, heteroaryl, and 3-6 membered heterocycloalkyl (e.g., with 1-4 heteroatoms), wherein each of said alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, aryl, heteroaryl and heterocycloalkyl are independently optionally substituted by one or more halo, hydroxy, nitro, cyano, C 1-6 alkyl (e.g., methyl), haloC 1-6 alkyl (e.g., CH 2 F, CHF 2 , CF 3 ), C 1-6 alkoxy (e.g., methoxy), or C 3-6 cycloalkyl (e.g., cyclopropyl);
each R 1 is independently selected from H, halo (e.g., fluoro), hydroxy, —CONH 2 , —CONR 2 R 3 , —SONH 2 , —SONR 2 R 3 , —SO 2 NH 2 , —SO 2 NR 2 R 3 , —NHCOC 1-3 alkyl (optionally substituted by 1 or more halo), —NR 2 COC 1-3 alkyl (optionally substituted by 1 or more halo), —NR 2 SO 2 C 1-3 alkyl (optionally substituted by 1 or more halo), —NR 2 SOC 1-3 alkyl (optionally substituted by 1 or more halo), cyano, C 1-6 alkyl (e.g., methyl), C 2-6 alkenyl (e.g., vinyl), or C 2-6 alkynyl (e.g., ethynyl), NR 2 R 3 , haloC 1-6 alkyl (e.g., CH 2 F, CHF 2 , CF 3 ), C 1-6 alkoxy (e.g., methoxy), C 3-6 cycloalkyl (e.g., cyclopropyl), or, if applicable, taken together with an R 1 on an adjacent atom, together with the atoms they are attached to, form a 3-6 membered heterocycloalkyl, 3-6 membered heterocycloalkenyl, C 3-6 cycloalkyl, C 3-6 cycloalkenyl, aryl, or heteroaryl ring system, wherein each of said alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, aryl, heteroaryl and heterocycloalkyl are independently optionally substituted by one or more halo, hydroxy, nitro, cyano, C 1-6 alkyl (e.g., methyl), haloC 1-6 alkyl (e.g., CH 2 F, CHF 2 , CF 3 ), C 1-6 alkoxy (e.g., methoxy), or C 3-6 cycloalkyl (e.g., cyclopropyl); and
each R 2 and R 3 is independently selected from H, halo, C 1-6 alkyl (e.g., methyl), C 3-6 cycloalkyl (e.g., cyclopropyl), or taken together with the atom they are attached to, form a 3-8 membered ring system containing 0-2 heteroatoms, wherein said alkyl or cycloalkyl is optionally substituted with one or more halo or hydroxy.
4 . The compound according to claim 3 , wherein A has the general structure:
wherein each of Q 1 , Q 2 , and Q 3 are independently selected from O, S, NR 2 , C 1-3 alkyl (e.g., CH 2 or CH 2 CH 2 or CH 2 CH 2 CH 2 ), optionally substituted by one or more R 1 , or wherein Q 1 or Q 2 is absent.
5 . The compound according to claim 4 , wherein Q 2 is absent, and Q 1 and Q 3 are independently selected from O, S, NR 2 , C 1-3 alkyl (e.g., CH 2 or CH 2 CH 2 or CH 2 CH 2 CH 2 ), optionally substituted by one or more R 1 .
6 . The compound according to claim 5 , wherein Q 1 is CH 2 or CH 2 CH 2 or CH 2 CH 2 CH 2 , and Q 3 is selected from O, S, and NH.
7 . The compound according to claim 4 , wherein Q 1 is absent, and Q 2 and Q 3 are independently selected from O, S, NR 2 , C 1-3 alkyl (e.g., CH 2 or CH 2 CH 2 or CH 2 CH 2 CH 2 ), optionally substituted by one or more R 1 .
8 . The compound according to claim 7 , wherein Q 2 is CH 2 or CH 2 CH 2 or CH 2 CH 2 CH 2 , and Q 3 is selected from O, S, and NH.
9 . The compound according to claim 1 , wherein B is aryl (e.g., phenyl) or heteroaryl (e.g., pyridyl or imidazolyl) optionally substituted by one or more groups selected from halo (e.g., fluoro), hydroxy, C 1-6 alkyl (e.g., methyl), haloC 1-6 alkyl (e.g., CH 2 F, CHF 2 , CF 3 ), and C 1-6 alkoxy (e.g., methoxy).
10 . The compound according to claim 1 , wherein the AR binding moiety is selected from:
11 . The compound according to claim 1 , wherein the linker (“L”) consists of a chemical structural unit represented by the formula -A q -, in which q is an integer greater than 1, and A is independently selected from the group consisting of: a bond, CR L1 R L2 , O, S, SO, SO 2 , NR L3 , SO 2 NR L3 , SONR L3 , CONR L3 , NR L3 CONR L4 , NR L3 SO 2 NR L4 , CO, CR L1 ═CR L2 , C≡C, SiR L1 R L2 , P(O)R L1 , P(O)OR L, NR L3 C(═NCN)NR L4 , NR L3 C(═NCN), NR L3 C(═CNO 2 )NR L4 , C 3-6 cycloalkyl, 3-6 membered heterocycloalkyl, aryl, and heteroaryl, wherein said cycloalkyl, heterocycloalkyl, aryl and heteroaryl are each optionally substituted with 0-6 R L1 and/or 0-6 R L2 groups; and wherein
R L1 , R L2 , R L3 , R L4 and R L5 are each independently selected from the group consisting of H, halo, C 1-8 alkyl, OC 1-8 alkyl, SC 1-8 alkyl, NHC 1-8 alkyl, N(C 1-8 alkyl) 2 , C 3-11 cycloalkyl, aryl, heteroaryl, 3-6 membered heterocycloalkyl, OC 1-8 cycloalkyl, SC 1-8 cycloalkyl, NHC 1-8 cycloalkyl, N(C 1-8 cycloalkyl) 2 , N(C 1-8 cycloalkyl)(C 1-8 alkyl), OH, NH 2 , SH, SO 2 C 1-8 alkyl, P(O)(OC 1-8 alkyl)(C 1-8 alkyl), P(O)(OC 1-8 alkyl) 2 , CC—C 1-8 alkyl, CCH, CH═CH(C 1-8 alkyl), C(C 1-8 alkyl)═CH(C 1-8 alkyl), C(C 1-8 alkyl)═C(C 1-8 alkyl) 2 , Si(OH) 3 , SiC( 1-8 alkyl) 3 , Si(OH)(C 1-8 alkyl) 2 , COC 1-8 alkyl, CO 2 H, CN, haloC 1-8 alkyl (e.g., CF 3 , CHF 2 , CH 2 F), NO 2 , SF 5 , SO 2 NHC 1-8 alkyl, SO 2 NHC 1-8 alkyl, SO 2 N(C 1-8 alkyl) 2 , SONHC 1-8 alkyl, SON(C 1-8 alkyl) 2 , CONHC 1-8 alkyl, CON(C 1-8 alkyl) 2 , N(C 1-8 alkyl)CONH(C 1-8 alkyl), N(C 1-8 alkyl)CON(C 1-8 alkyl) 2 , NHCONH(C 1-8 alkyl), NHCON(C 1-8 alkyl) 2 , NHCONH 2 , N(C 1-8 alkyl)SO 2 NH(C 1-8 alkyl), N(C 1-8 alkyl)SO 2 N(C 1-8 alkyl) 2 , NHSO 2 NH(C 1-8 alkyl), NHSO 2 N(C 1-8 alkyl) 2 and NHSO 2 NH 2 ; and wherein R L and R L2 each, independently may be linked to another A group to form a cycloalkyl and or heterocycloalkyl moiety that can be further substituted with 0-4 R L5 groups.
12 . The compound according to claim 1 , wherein the compound comprises:
the AR binding moiety
and wherein the E3 ligase binding moiety is
wherein R 8 is C 1-6 alkyl (e.g., tert-butyl); R 10 is optionally substituted C 1-6 alkyl (e.g., methyl or tert-butyl) or C 3-6 cycloalkyl (e.g., cyclohexyl); R 11 is optionally substituted C 3-10 cycloalkyl (e.g., cyclopropyl or halo-substituted cyclopropyl);
or the E3 ligase binding moiety is
wherein “ ” in the above structures, represents a bond that may be stereospecific ((R) or (S)), or non-stereospecific, and wherein:
each R 1 is independently selected from H and halo (e.g., fluoro, chloro, or bromo), and wherein R 4 is H; and
wherein L consists of a set of moieties A selected from CH 2 , O, NH, NCH 3 , CONH, CO, cyclopropyl, cyclobutyl, morpholinyl, piperidinyl, piperazinyl, azetidinyl, phenyl, pyridinyl, pyrimidinyl, triazolyl, oxadiazolyl, imidazolyl, pyrazolyl, isoxazolyl, thiazolyl, isothiazolyl, thiophenyl, furanyl, and pyrrolyl, optionally wherein at least one moiety A is selected from cyclopropyl, cyclobutyl, morpholinyl, piperidinyl, piperazinyl, azetidinyl, phenyl, pyridinyl, pyrimidinyl, triazolyl, oxadiazolyl, imidazolyl, pyrazolyl, isoxazolyl, thiazolyl, isothiazolyl, thiophenyl, furanyl, and pyrrolyl.
13 . The compound according to claim 1 , wherein the compound comprises:
the AR binding moiety
and wherein the E3 ligase binding moiety is:
and
wherein L consists of a set of moieties A selected from CH 2 , O, NH, NCH 3 , CONH, CO, cyclopropyl, cyclobutyl, morpholinyl, piperidinyl, piperazinyl, azetidinyl, phenyl, pyridinyl, pyrimidinyl, triazolyl, oxadiazolyl, imidazolyl, pyrazolyl, isoxazolyl, thiazolyl, isothiazolyl, thiophenyl, furanyl, and pyrrolyl, optionally wherein at least one moiety A is selected from cyclopropyl, cyclobutyl, morpholinyl, piperidinyl, piperazinyl, azetidinyl, phenyl, pyridinyl, pyrimidinyl, triazolyl, oxadiazolyl, imidazolyl, pyrazolyl, isoxazolyl, thiazolyl, isothiazolyl, thiophenyl, furanyl, and pyrrolyl.
14 . The compound according to claim 1 , wherein the compound comprises:
the AR binding moiety
and wherein the E3 ligase binding moiety is:
and
wherein L consists of a set of moieties A selected from CH 2 , O, NH, NCH 3 , CONH, CO, cyclopropyl, cyclobutyl, morpholinyl, piperidinyl, piperazinyl, azetidinyl, phenyl, pyridinyl, pyrimidinyl, triazolyl, oxadiazolyl, imidazolyl, pyrazolyl, isoxazolyl, thiazolyl, isothiazolyl, thiophenyl, furanyl, and pyrrolyl, optionally wherein at least one moiety A is selected from cyclopropyl, cyclobutyl, morpholinyl, piperidinyl, piperazinyl, azetidinyl, phenyl, pyridinyl, pyrimidinyl, triazolyl, oxadiazolyl, imidazolyl, pyrazolyl, isoxazolyl, thiazolyl, isothiazolyl, thiophenyl, furanyl, and pyrrolyl.
15 . The compound according to claim 1 , wherein the compound comprises:
the AR binding moiety
and wherein the E3 ligase binding moiety is:
optionally wherein, in each of said compounds, the “ ” bond is oriented to form the (R)-chiral carbon, and
wherein L consists of a set of moieties A selected from CH 2 , O, NH, NCH 3 , CONH, CO, cyclopropyl, cyclobutyl, morpholinyl, piperidinyl, piperazinyl, azetidinyl, phenyl, pyridinyl, pyrimidinyl, triazolyl, oxadiazolyl, imidazolyl, pyrazolyl, isoxazolyl, thiazolyl, isothiazolyl, thiophenyl, furanyl, and pyrrolyl, optionally wherein at least one moiety A is selected from cyclopropyl, cyclobutyl, morpholinyl, piperidinyl, piperazinyl, azetidinyl, phenyl, pyridinyl, pyrimidinyl, triazolyl, oxadiazolyl, imidazolyl, pyrazolyl, isoxazolyl, thiazolyl, isothiazolyl, thiophenyl, furanyl, and pyrrolyl.
16 . The compound according to claim 13 , wherein L consists of a set of moieties A selected from CH 2 , O, NH, CONH, CO, cyclobutyl, morpholinyl, piperidinyl, piperazinyl, azetidinyl, and triazolyl, optionally wherein at least one moiety A is cyclobutyl, morpholinyl, piperidinyl, piperazinyl, azetidinyl, or triazolyl.
17 . The compound according to claim 13 , wherein L consists of a set of moieties A selected from CH 2 , O, NH, CONH, and CO.
18 . The compound according to claim 17 , wherein L does not comprise any alkyl chain having more than 3 carbons (e.g., L may comprise subunits selected from —CH 2 —, —CH 2 CH 2 —, and —CH 2 CH 2 CH 2 —), optionally wherein L comprises one or more ethyleneoxy subunits (e.g., —CH 2 CH 2 O—).
19 . A compound selected from the group consisting of:
20 . A pharmaceutical composition comprising a compound according to claim 1 , and a pharmaceutically acceptable carrier, additive and/or excipient.
21 . A method of treating a disease state or condition in a patient wherein dysregulated protein activity is responsible for said disease or condition, said method comprising administering an effective amount of a compound according to claim 1 , to a patient in need thereof.
22 . A method of degrading an androgen receptor in a cell, e.g., a mutated AR such as any AR-V1 to AR-V15 splice variant, e.g., the AR-V7 splice variant, said method comprising administering an effective amount of a compound according to claim 1 , to such cell, e.g., a cancer cell.
23 . A method of inducing apoptosis in a cell, e.g., a cancer cell, said method comprising administering an effective amount of a compound according to claim 1 , to such cell.